Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
Revenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency 1 Basis Compared to the Second Quarter...
Barchart Research What to Expect from BLCO Earnings BLCO Generated July 28, 2026 Current Price $16.61 EPS Estimate $$0.16 Consensus Rating Hold Average Move 3.83% Bausch & Lomb's Revenue Momentum Meets...
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead
EyeGility is designed for the enVista® family of IOLs Offers balanced push force for smooth delivery, convenient one-handed operation ...
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant...
Designed to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities...